文献速递免疫规划卫生政策与健康促进传染病防控与疫情报告

估算2020—2030年112个国家COVID-19相关免疫规划中断的健康影响:一项模型研究

Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.
PubMed 文献 · Lancet Glob Health · 2024-01-01

该模型研究由疫苗影响建模联盟的多家建模团队开展,覆盖112个低收入和中等收入国家、14种病原体,使用1937—2021年疫苗覆盖率数据,模拟无中断、基线恢复、基线恢复加补种三种情景。结果显示,麻疹、风疹、HPV、乙型肝炎、A群脑膜炎和 Yellow fever 疫苗接种中断可能在2020—2030日历年内导致49 119例额外死亡(95%可信区间17 248—134 941),其中大部分由麻疹所致。

要点

  • 麻疹、风疹、HPV、乙肝、A群脑膜炎和黄热病接种中断在2020—2030年或致49 119例额外死亡(95%CrI 17 248—134 941),以麻疹为主。
  • 14种病原体2020—2030年接种队列的长期效果或下降2·66%(95%CrI 2·52—2·81),由37 378 194例死亡避免降至36 410 559例。
  • 补种活动在2023—2030日历年内或可避免78·9%的额外死亡(95%CrI 40·4—151·4)。

核心结论

  • COVID-19相关免疫规划中断可使麻疹、风疹、HPV、乙肝、A群脑膜炎和黄热病接种在2020—2030日历年内产生49 119例额外死亡(95%CrI 17 248—134 941),以麻疹为主。
  • 14种病原体2020—2030年接种队列的长期效果或下降2·66%(95%CrI 2·52—2·81),由37 378 194例死亡避免(34 450 249—40 241 202)降至36 410 559例(33 515 397—39 241 799)。
  • 补种活动在2023—2030日历年内或可避免78·9%(40·4—151·4)的额外死亡,即25 356例(9 859—75 073)中的18 900例(7 037—60 223)。
  • 作者认为,补种活动的时机应结合估算负担来考虑,以改善受影响队列的疫苗覆盖率。
  • 作者认为,麻疹和黄热病的缓解措施在短期内减少额外负担方面尤其有效。

研究设计与样本

  • 该研究为模型研究,使用疫苗影响建模联盟来自112个低收入和中等收入国家的建模团队,估算14种病原体的疫苗效果。
  • 恢复运行使用1937—2021年疫苗覆盖率数据,覆盖麻疹、风疹、乙型肝炎、人乳头瘤病毒(HPV)、A群脑膜炎和黄热病,用于评估缓解措施。
  • 完整运行使用1937—2020年疫苗覆盖率数据,用于计算全部14种纳入疫苗和疾病的效应比(即每剂避免的负担)。
  • 两项运行均模拟2000年1月1日至2100年12月31日;纳入国家属于Gavi、疫苗联盟组合,或具有显著负担,或具有显著战略性疫苗接种活动。
  • 疫苗覆盖率依据WHO-UNICEF国家免疫覆盖率估算和WHO免疫储存库截至2021年的历史估计;2022年起依据运动频率指导、常规免疫恢复至中断前水平的非线性假设,以及以WHO免疫议程2030目标和专家咨询为依据的2030终点进行估算。

主要发现

  • 麻疹、风疹、HPV、乙肝、A群脑膜炎和黄热病接种中断可能在2020—2030日历年内导致49 119例额外死亡(95%CrI 17 248—134 941),大部分由麻疹所致。
  • 全部14种病原体2020—2030年接种队列的长期效果或下降2·66%(95%CrI 2·52—2·81),由37 378 194例死亡避免(34 450 249—40 241 202)降至36 410 559例(33 515 397—39 241 799)。
  • 补种活动在2023—2030日历年内或可避免78·9%(40·4—151·4)的额外死亡,即25 356例(9 859—75 073)中的18 900例(7 037—60 223)。

关键数值与推荐

  • 研究以效应比(每剂避免的负担)作为指标,对全部14种纳入疫苗和疾病进行估算。
  • 研究以额外死亡数和长期效果变化(死亡避免数)作为中断影响的主要量化指标,数值及95%CrI见主要发现。

临床怎么用

  • 作者认为,补种活动的时机应结合估算负担来考虑,以改善受影响队列的疫苗覆盖率。
  • 作者认为,麻疹和黄热病的缓解措施在短期内减少额外负担方面尤其有效。
  • 作者认为,HPV疫苗作为宫颈癌预防工具具有高长期效果,值得在中断后继续开展免疫工作。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This disruption has led to under-immunised cohorts and interrupted progress in reducing vaccine-preventable disease burden. There have, so far, been few studies of the effects of coverage disruption on vaccine effects. We aimed to quantify the effects of vaccine-coverage disruption on routine and campaign immunisation services, identify cohorts and regions that could particularly benefit from catch-up activities, and establish if losses in effect could be recovered. METHODS: For this modelling study, we used modelling groups from the Vaccine Impact Modelling Consortium from 112 low-income and middle-income countries to estimate vaccine effect for 14 pathogens. One set of modelling estimates used vaccine-coverage data from 1937 to 2021 for a subset of vaccine-preventable, outbreak-prone or priority diseases (ie, measles, rubella, hepatitis B, human papillomavirus [HPV], meningitis A, and yellow fever) to examine mitigation measures, hereafter referred to as recovery runs. The second set of estimates were conducted with vaccine-coverage data from 1937 to 2020, used to calculate effect ratios (ie, the burden averted per dose) for all 14 included vaccines and diseases, hereafter referred to as full runs. Both runs were modelled from Jan 1, 2000, to Dec 31, 2100. Countries were included if they were in the Gavi, the Vaccine Alliance portfolio; had notable burden; or had notable strategic vaccination activities. These countries represented the majority of global vaccine-preventable disease burden. Vaccine coverage was informed by historical estimates from WHO-UNICEF Estimates of National Immunization Coverage and the immunisation repository of WHO for data up to and including 2021. From 2022 onwards, we estimated coverage on the basis of guidance about campaign frequency, non-linear assumptions about the recovery of routine immunisation to pre-disruption magnitude, and 2030 endpoints informed by the WHO Immunization Agenda 2030 aims and expert consultation. We examined three main scenarios: no disruption, baseline recovery, and baseline recovery and catch-up. FINDINGS: We estimated that disruption to measles, rubella, HPV, hepatitis B, meningitis A, and yellow fever vaccination could lead to 49 119 additional deaths (95% credible interval [CrI] 17 248-134 941) during calendar years 2020-30, largely due to measles. For years of vaccination 2020-30 for all 14 pathogens, disruption could lead to a 2·66% (95% CrI 2·52-2·81) reduction in long-term effect from 37 378 194 deaths averted (34 450 249-40 241 202) to 36 410 559 deaths averted (33 515 397-39 241 799). We estimated that catch-up activities could avert 78·9% (40·4-151·4) of excess deaths between calendar years 2023 and 2030 (ie, 18 900 [7037-60 223] of 25 356 [9859-75 073]). INTERPRETATION: Our results highlight the importance of the timing of catch-up activities, considering estimated burden to improve vaccine coverage in affected cohorts. We estimated that mitigation measures for measles and yellow fever were particularly effective at reducing excess burden in the short term. Additionally, the high long-term effect of HPV vaccine as an important cervical-cancer prevention tool warrants continued immunisation efforts after disruption. FUNDING: The Vaccine Impact Modelling Consortium, funded by Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation. TRANSLATIONS: For the Arabic, Chinese, French, Portguese and Spanish translations of the abstract see Supplementary Materials section.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Hartner AM, Li X, Echeverria-Londono S, et al. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study. Lancet Glob Health. 2024. PMID: 38485425. doi:10.1016/S2214-109X(23)00603-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。